Scotland A Research Ethics Committee

Research Ethics Service
2nd Floor Waverley Gate
2-4 Waterloo Place
Edinburgh
EH1 3EG
Tel: 0131 465 5680
www.hra.nhs.uk

Enquiries to: Manx Neill
Work Mobile: 07814609032
Office Direct Line: 0131 465 5678
E-mail: manx.neill@nhslothian.scot.nhs.uk

11 June 2020

Dr Tim England
Clinical Associate Professor in Stroke Medicine
University of Nottingham
Vascular Medicine, Division of Medical Sciences & GEM
The Medical School, Royal Derby Hospital, Uttoxeter Rd
Derby
DE22 3NE

Dear Dr England,

Study title:	**Remote Ischaemic Conditioning After Stroke 3 (RECAST-3): A multicentre randomised controlled trial**
REC reference:	**20/SS/0047**
Protocol number:	**20011**
IRAS project ID:	**282606**

The Research Ethics Committee reviewed the above application at the meeting held on 28 May 2020. Thank you for attending to discuss the application.

Ethical opinion

The members of the Committee present gave a favourable ethical opinion of the above research on the basis described in the application form, protocol and supporting documentation, subject to the conditions specified below. .

Adults with Incapacity (Scotland) Act 2000

I confirm that the Committee has approved this research project for the purposes of the Adults with Incapacity (Scotland) Act 2000. The Committee is satisfied that the requirements of section 51 of the Act will be met in relation to research carried out as part of this project on, or in relation to, a person who lacks capacity to consent to taking part in the project.

The Committee wished to make the following recommendations.

Number	Recommendations
1	The Committee noted that at A17.2 in the REC form in the Exclusions section it stated that "On treatment for diabetes would be excluded." The Committee asked the researcher if this was

	correct. *The researcher explained that no, this was not the case anymore.* The Committee is aware that this has already been given a FO by the greater Manchester South REC but would recommend that the IRAS Form be corrected to reflect this fact.
2	The Committee spoke to the researcher about the fact that the title of the PIS was Remote Conditioning and wondered why the word Ischaemic had been removed. The researcher told the Committee that it had been removed as it was felt that it was not lay friendly language, but could be introduced if need be. The Committee told the researcher that the first paragraph of the PIS document refers to Remote Ischaemic Conditioning and recommended that it might be more beneficial if either this was rephrased or the title was changed to include the term Ischaemic as well. [Recommendation 2] The researcher should bear in mind that these are just recommendations and do not need to be implemented as part of the Favourable Opinion that has been issued by Scotland A REC. If the researcher did decide to implement these changes it would be the Greater Manchester REC that they would inform about them (as this is the initial reviewing REC). It is ultimately the Sponsor's decision whether any changes made are considered to be Substantial or minor (Non-Substantial). Ordinarily however, any changes to the REC form such as that of the diabetes not being a part of the exclusion criteria would not require a resubmission of the REC Form itself, a Cover letter on headed paper explaining the change that had been made and why this was felt necessary sent to the REC would suffice. Changing the title of the PIS to reflect the information given in the opening paragraph of the document would normally be classed as a minor amendment and the REC would not need to be informed of this change or sent the amended paperwork for such a change.

Conditions of the favourable opinion

The REC favourable opinion is subject to the following conditions being met prior to the start of the study.

Confirmation of Capacity and Capability (in England, Northern Ireland and Wales) or NHS management permission (in Scotland) should be sought from all NHS organisations involved in the study in accordance with NHS research governance arrangements. Each NHS organisation must confirm through the signing of agreements and/or other documents that it has given permission for the research to proceed (except where explicitly specified otherwise).

Guidance on applying for HRA and HCRW Approval (England and Wales)/ NHS permission for research is available in the Integrated Research Application System.

For non-NHS sites, site management permission should be obtained in accordance with the procedures of the relevant host organisation.

Sponsors are not required to notify the Committee of management permissions from host organisations.

Registration of Clinical Trials

It is a condition of the REC favourable opinion that **all clinical trials are registered** on a publicly accessible database. For this purpose, 'clinical trials' are defined as the first four project categories in IRAS project filter question 2. Registration is a legal requirement for clinical trials of investigational medicinal products (CTIMPs), except for phase I trials in healthy volunteers (these must still register as a condition of the REC favourable opinion).

Registration should take place as early as possible and within six weeks of recruiting the first research participant at the latest. Failure to register is a breach of these approval conditions, unless a deferral has been agreed by or on behalf of the Research Ethics Committee (see here for more information on requesting a deferral: https://www.hra.nhs.uk/planning-and-improving-research/research-planning/research-registration-research-project-identifiers/

As set out in the UK Policy Framework, research sponsors are responsible for making information about research publicly available before it starts e.g. by registering the research project on a publicly accessible register. Further guidance on registration is available at: https://www.hra.nhs.uk/planning-and-improving-research/research-planning/transparency-responsibilities/

You should notify the REC of the registration details. We routinely audit applications for compliance with these conditions.

Publication of Your Research Summary

We will publish your research summary for the above study on the research summaries section of our website, together with your contact details, no earlier than three months from the date of this favourable opinion letter. Should you wish to provide a substitute contact point, make a request to defer, or require further information, please visit: https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/

For research studies related to COVID-19, we are fast-tracking the publication of research summaries. During this public health emergency, it is vital that everyone can promptly identify all relevant research related to COVID-19 that is taking place globally. If you have not already done so, please register your study on a public registry as soon as possible and provide the HRA with the registration detail, which will be posted alongside other information relating to your project. We are also asking sponsors not to request deferral of publication of research summary for any projects relating to COVID-19. In addition, to facilitate finding and extracting studies related to COVID-19 from public databases, please enter the WHO official acronym for the coronavirus disease (COVID-19) in the full title of your study. Approved COVID-19 studies can be found at: https://www.hra.nhs.uk/covid-19-research/approved-covid-19-research/

Notice of no objection must be obtained from the Medicines and Healthcare products Regulatory Agency (MHRA).

The sponsor is asked to provide the Committee with a copy of the notice from the MHRA, either confirming no objection or giving grounds for objection, as soon as this is available.

It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of the study or its initiation at a particular site (as applicable).

After ethical review: Reporting requirements

The attached document "After ethical review – guidance for researchers" gives detailed guidance on reporting requirements for studies with a favourable opinion, including:

- Notifying substantial amendments
- Adding new sites and investigators
- Notification of serious breaches of the protocol
- Progress and safety reports
- Notifying the end of the study, including early termination of the study
- Final report

The latest guidance on these topics can be found at https://www.hra.nhs.uk/approvals-amendments/managing-your-approval/.

Ethical review of research sites

NHS/HSC Sites

The favourable opinion applies to all NHS/HSC sites taking part in the study taking part in the study, subject to confirmation of Capacity and Capability (in England, Northern Ireland and Wales) or NHS management permission (in Scotland)being obtained from the NHS/HSC R&D office prior to the start of the study (see "Conditions of the favourable opinion" below).

Non-NHS/HSC sites

I am pleased to confirm that the favourable opinion applies to any non NHS/HSC sites listed in the application, subject to site management permission being obtained prior to the start of the study at the site.

Approved documents

The documents reviewed and approved at the meeting were:

Document	*Version*	*Date*
Covering letter on headed paper [Cover letter]	1.0	03 April 2020
Evidence of Sponsor insurance or indemnity (non NHS Sponsors only) [Insurance]	1.0	30 July 2019
GP/consultant information sheets or letters [GP letter]	1.0	29 January 2020
Instructions for use of medical device [Technical dossier]	1.0	29 January 2020
IRAS Application Form [IRAS_Form_06042020]		06 April 2020
Letter from funder [Funder letter]	1.0	06 November 2019

Letter from sponsor [Sponsorship letter]	1.0	10 March 2020
MHRA Notice of No Objection Letter (Medical Devices) and relevant correspondence	1.0	10 March 2020
Other [CE Mark]	1.0	02 October 2017
Other [Medico technical testing]	1.0	15 January 2018
Other [English REC provisional outcome]		
Other [NIHR contract]		
Other [WA consent]	1.2	29 April 2020
Other [PIS reconsent (Scotland)]	1.1	29 April 2020
Other [PIS]	1.2	29 April 2020
Other [MRI consent]	1.2	29 April 2020
Other [Consent]	1.2	29 April 2020
Other [WA PIS]	1.2	29 April 2020
Other [Updated protocol]	1.1	29 April 2020
Participant consent form [Consultee advice]	1.0	06 March 2020
Participant information sheet (PIS) [PIS reconsent]	1.0	06 March 2020
Summary CV for Chief Investigator (CI) [CI CV]		21 December 2019

Membership of the Committee

The members of the Ethics Committee who were present at the meeting are listed on the attached sheet.

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

User Feedback

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website: http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/

HRA Learning

We are pleased to welcome researchers and research staff to our HRA Learning Events and online learning opportunities– see details at: https://www.hra.nhs.uk/planning-and-improving-research/learning/

IRAS project ID: 282606 Please quote this number on all correspondence

With the Committee's best wishes for the success of this project.

Yours sincerely



Dr Ian Zealley
Chair

E-mail: Manx.Neill@nhslothian.scot.nhs.uk

Enclosures: List of names and professions of members who were present at the meeting and those who submitted written comments

"After ethical review – guidance for researchers" [SL-AR2 for other studies]

Copy to: *Ms Angela Shone*
Lead Nation: England: approvals@hra.nhs.uk

Scotland A REC

Attendance at Committee meeting on 28 May 2020

Committee Members:

Name	*Profession*	*Present*	*Notes*
Mr Graham Ayres	Solicitor	Yes	
Dr Jill Bradshaw	Senior Lecturer in Intellectual and Developmental Disability	Yes	
Dr Laura Doull	Clinical Brain Sciences Project Manager	Yes	
Dr Jessica MacLaren	Registered Nurse-Lecturer in Mental Health	Yes	
Dr Mary-Joan Macleod	Clinical Pharmacologist/Consultant Physician	Yes	
Mrs Joanne Mair	Researcher	Yes	
Miss Erin Miley	Registered Speech & Language Therapist.	Yes	
Dr Anthony Pottage	Retired Physician/Clinical Pharmacologist	Yes	
Dr Lindsay Ramage	Head Of Research Governance	Yes	
Dr Jacqueline Stephen	Trial Statistician	Yes	
Dr Charles Wallis	Consultant in Anaesthesia & Intensive Care	Yes	
Dr Hester Ward	Public Health Consultant	Yes	
Mr Robert Wyllie	COVID-19 Clinical Guidance Cell Secretariat, Chief Medical Officer's Directorate	No	
Dr Ian Zealley	Consultant In Department Of Radiology	Yes	

Also in attendance:

Name	*Position (or reason for attending)*
Mrs Agnieszka Di Domenico Prada	SESREC Administrative Officer
Manx Neill	Scotland A/B REC Manager
Dr Helen Newbery	Scientific Officer